Jack Kenney is the Chief Executive Officer of Divergence Labs, which he founded in 2025. Prior to Divergence Labs, Jack was an Investor at Estuary Capital Management, a global long/short equity investment firm, where he was responsible for identifying and researching public investments, primarily in the healthcare sector. He was also a member of the investment team at SV Health Investors, where he was responsible for the identification, evaluation, and incubation of private biotechnology companies. Jack started his career at ClearView Healthcare Partners. He received an M.S. from the University of Notre Dame and an A.B. in Chemistry and Economics from the College of the Holy Cross.

Nikhil Mallipeddi is the President at Divergence Labs, which he co-founded in 2025. Prior to Divergence Labs, Nikhil was an Investor at Citadel, a global multi-strategy investment firm, where he was responsible for identifying, researching, and managing public investments, primarily in life sciences and biotechnology. He was also a member of the investment team at Softbank Investment Advisers, where he focused on private life sciences investments. Nikhil started his career as a strategy consultant at McKinsey & Company. He received a Master in Public Health in Healthcare Policy and Administration and a B.A. in Biology from Case Western Reserve University.

David Holmes, Ph.D. is the Head of Engineering at Divergence Labs, which he joined in 2025 to found the Engineering team. Prior to Divergence Labs, David was the Vice President of Product Development at Cell Microsystems and Vice President of Discovery Platforms at 1859, Inc. While at 1859, Inc., he was a member of the Senior Leadership team with overall operational responsibility for the development of high-throughput screeening systems. Earlier in his career, David was the Director and Head of Physics and Engineering at Sphere Fluidics Limited, where he was the core team leader responsible for the development and launch of Cyto-Mine®, a fully-automated cellular analysis platform to encapsulate, analyze, sort, and dispense single cells. He received his Ph.D. in Bioelectronics, B.Eng. in Electical Engineering, and BSc. in Neuroscience from the University of Glasgow, and completed Fellowships at the University of Southhampton and UCL London Centre for Nanotechnology.

Nathan Mallipeddi, MD is the Head of Investment Research at Divergence Labs, which he joined in 2025 as founding member of the Investment team. Prior to Divergence Labs, Nathan was a member of the investment team at RA Capital Management, a global investment firm focused on biotechnology. He received an M.D. from Harvard Medical School, where he was a Paul & Daisy Soros Fellow, and a B.S. in Biology and B.A. in Political Science from UCLA, where he graduated Phi Beta Kappa and summa cum laude. During his undergraduate studies, Nathan founded MySpeech, an international nonprofit organiation that enables people who stutter to access personalized speech therapy and other crucial resources. Nathan continues to serve as the Executive Chairman of MySpeech.

Dimitris Josephides, Ph.D. is a Director of Engineering at Divergence Labs, which he joined in 2025. Prior to Divergence Labs, Dimitris served as Principal Engineer and Head of Microfluidics at Sphere Fluidics Limited, where he spent a decade designing and managing instrumentation for high-throughput characterization of potential therapeutics. He received his Ph.D. in Mechanical Engineering and Physics from King's College London. He also received an MEng in Mechanical Engineering, First Class, from King's College London.

Ru Wang, Ph.D. is a Senior Engineer at Divergence Labs, which she joined in 2025. Prior to Divergence Labs, Ru was a Senior Engineer at Sphere Fluidics Limited, where she was responsible for designing, prototyping, and testing novel approaches for reliably screening and characterizing large amounts of single cells. Prior to joining Sphere, Ru received her Ph.D. in Chemical Engineering annd Biotechnology and an MPhil in Advanced Chemical Engineering from the University of Cambridge. She also received an Engineering and Master of Science degree in Chemistry from Chimie ParisTech - PSL.

Joel Rogers, Ph.D. is a Scientist at Divergence Labs, which he joined in 2025. Prior to Divergence Labs, Joel was a Research Associate at University of Cambridge, where he developed and implemented high-throughput phenotypic screens for therapeutic proteins. Joel completed his Ph.D. and MSci in Biochemistry at the University of Cambridge, where he graduated with First Class honors.

Tim Harris, Ph.D. is the Chairman of Research & Development at Divergence Labs and serves on the Board of Directors. Tim Harris has been an Operating Partner at SV Health Investors, a healthcare venture capital firm, since 2016. Prior to joining SV, Tim was Executive Vice President of Research & Development at Biovertiv, where he was responsible for all aspects of R&D prior to the acquisition of Bioverativ for $11.6B by Sanofi. Additionally, Tim served as the Senior Vice President for Precision Medicine and Translational Medicine at Biogen. Tim joined the biotechnology industry at its inception in 1978 as one of the first scientists hired by Celltech. He received his BSc, Ph.D., and DSc from the University of Birmingham.

Nils Lonberg, Ph.D. is an Advisor at Divergence Labs, where he serves on the R&D Investment Committee to support program nomination and decision-making. Nils has been an Executive in Residence at Canaan Partners, a venture capital firm, since 2019. Prior to joining Canaan, Nils was Senior Vice President of Oncology Discovery Biology at Bristol-Myers Squibb, where he led drug discovery efforts for both targeted and immuno-oncology agents, including the development of Yervoy and Opdivo, the first FDA approved checkpoint inhibitors. Earlier in his career, he served as a Scientific Director at GenPharm and Medarex. He received his Ph.D. in Biochemistry and Molecular Biology from Harvard University in 1985 and was elected to the National Academy of Engineering in 2015.

Mike Ross, Ph.D. is an Advisor at Divergence Labs, where he serves on the R&D Investment Committee to support program nomination and decision-making. Mike is a Senior Partner at SV Health Investors, which he joined in 2001 as a Venture Partner and became a Managing Partner in 2002. Prior to joining SV Health Investors, he was a serial enterpreneur, founding Arris Pharmaceuticals, which identified and synthesized Imbruvica, and also founding MetaXen, ExSAR, and CyThera. Earlier in his career, Mike was Vice President of Development at Genentech, which he joined as the tenth employee in 1978. While at Genentech, he served as the team leader for all major products, including Humulin (human insulin), Roferon (interferon alpha), and Protropin (hGH), among others. Following his time leading Development, he then started the Protein Engineering and Small Molecule Discovery groups within Genentech. Mike received his Ph.D. in Biophysics at Caltech and completed a his postdoctoral work in Molecular Biology at Harvard University. He serves on the Board of the Thayer School of Engineering at Dartmouth College, where he recieved his A.B. in Chemistry

Ali Tehrani, Ph.D. is an Advisor at Divergence Labs, where he serves on the R&D Investment Committee to support program nomination and decision-making. Ali is the Co-founder and Chief Executive Officer at DCx Biotherapeutics Corporation. Prior to founding DCx, Ali served as a Venture Partner and Partner at Amplitude Ventures, a venture capital firm based in Vancouver, British Columbia. Earlier in his career, he co-founded Zymeworks in 2003, where he led the growth of the company from 2 to 500 people over 18 years and executed 9 licensing deals with large pharmacueical companies, including Merck, J&J, GSK, Bristol Meyers Squibb, and Lilly. During his time leading Zymeworks, the company identified Ziihera, now approved to treat HER2+ cancers. Ali received his Ph.D. in Microbiology and Immunology from the University of British Columbia and an M.S. and BASc in Biochemistry from University of Massachusetts Amherst.

Omid Vafa, Ph.D. is an Advisor at Divergence Labs, where he serves on the R&D Investment Committee to support program nomination and decision-making. Omid served as the Chief Business Officer at Teneobio, Inc. from 2016 through its acquisition for up to $2.5B by Amgen in 2021. Prior to Teneo, Omid was a Director at Johnson & Johnson in the Biotechnology, Innovation, Evaluation & Licensing group. Earlier in his career, he was an antibody engineering Scientist at Xencor, Centocor, and Johnson & Johnson. He received his Master of Business Administration from Villanova University, received his Ph.D. in Biology and Biochemistry from Georgetown University, and completed postdoctoral research at Scripps and the Salk Institute. Omid received his B.S. in Biological Sciences from UC Irvine.

João Veira is an Advisor at Divergence Labs, where he serves on the R&D Investment Committee to support program nomination and decision-making, as well as supports antibody and protein engineering strategy. João joined Medicxi Ventures in 2025 as a Venture Partner. Prior to Medicxi, he served as the Head of Discovery at argenx, where he oversaw all antibody and protein therapeutic discovery efforts. Earlier in his career, he was a Director and Head of Pipeline Engineering at Adaptimmune and Team Leader at Ablynx. He received his BASc in Biochemistry and Applied Biochemistry from the Faculty of Science, University of Porto.

Sam Blackman, MD, Ph.D. is an Advisor at Divergence Labs, where he serves on the R&D Investment Committee to support program nomination and decision-making. Sam joined GV (Google Ventures) as an Entrepreneur in Residence in 2025. Prior to GV, Sam founded Day One Biopharmaceuticals in 2018, where he served as Chief Medical Officer and Head of Research & Development and was responsible for identification, development, and approval of Ojemda, the first FDA approved medicine for BRAF+ pediatric low-grade glioma (pLGG). Earlier in his career, he was the Head of Clinical Development at Mavupharma and Silverback Therapeutics, as well as a clinical development leader at Juno Therapeutics, Seattle Genetics, GSK, and Merck. Sam is a physician-scientist trained in pediatric hematology/oncology and neuro-oncology and has led the development of more than 10 novel cancer therapies. Dr. Blackman is a graduate of the pediatric hematology/oncology fellowship program at Dana-Farber Cancer Institute and Children's Hospital Boston. He received his MD and Ph.D. degrees from the University of Illinois at Chicago and an undergraduate degree in Philosophy from the University of Chicago. Sam serves as a Board Member of the Pediatric Brain Tumor Foundation and CureSearch for Children's Cancer.

Adam Goulburn, Ph.D. serves on the Board of Directors at Divergence Labs, which he co-founded in 2025. Adam is a Managing Partner at Dimension Capital, a technology and life sciences venture capital firm, which he co-founded in 2022. Prior to Dimension, he was a General Partner at Lux Capital, a global venture capital firm, during which he co-founded and incubated multiple companies, including Cajal Neuroscience, VNV Bio, and Kallyope, where he served as the founding Chief Executive Officer. Companies Adam has co-founded have raised over $500M to develop new medicines using cutting-edge technology. Prior to his career in venture, Adam completed a postdoctoral fellowship in Neuroscience at Weill Cornell Medical College. He received his Ph.D. and dual undergraduate degrees in Business and Science from the Australian Stem Cell Centre, where he was a Premier Scholar.